HUE043014T2 - Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárások - Google Patents
Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárásokInfo
- Publication number
- HUE043014T2 HUE043014T2 HUE15843405A HUE15843405A HUE043014T2 HU E043014 T2 HUE043014 T2 HU E043014T2 HU E15843405 A HUE15843405 A HU E15843405A HU E15843405 A HUE15843405 A HU E15843405A HU E043014 T2 HUE043014 T2 HU E043014T2
- Authority
- HU
- Hungary
- Prior art keywords
- ahu
- related methods
- supramolecular complex
- sodium containing
- containing valsartan
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title 1
- QCGGXGCODUUTLZ-UHFFFAOYSA-N [Na].[Na].[Na].[Na] Chemical compound [Na].[Na].[Na].[Na] QCGGXGCODUUTLZ-UHFFFAOYSA-N 0.000 title 1
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 title 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1
- 229960004699 valsartan Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089225P | 2014-12-08 | 2014-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE043014T2 true HUE043014T2 (hu) | 2019-07-29 |
Family
ID=55582176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15843405A HUE043014T2 (hu) | 2014-12-08 | 2015-12-08 | Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárások |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9957240B2 (enExample) |
| EP (2) | EP3443960A1 (enExample) |
| JP (3) | JP2017537120A (enExample) |
| CN (3) | CN110938042B (enExample) |
| AU (1) | AU2015319831B2 (enExample) |
| CA (1) | CA2970192C (enExample) |
| DK (1) | DK3229799T3 (enExample) |
| ES (1) | ES2706948T3 (enExample) |
| HU (1) | HUE043014T2 (enExample) |
| IL (2) | IL252740A0 (enExample) |
| MX (1) | MX383336B (enExample) |
| PL (1) | PL3229799T3 (enExample) |
| PT (1) | PT3229799T (enExample) |
| SI (1) | SI3229799T1 (enExample) |
| TR (1) | TR201900360T4 (enExample) |
| WO (1) | WO2016049663A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2016037552A1 (zh) * | 2014-09-09 | 2016-03-17 | 上海翰森生物医药科技有限公司 | 结晶型ARB-NEPi复合物及其制备方法和应用 |
| AU2015319831B2 (en) | 2014-12-08 | 2019-02-14 | Crystal Pharmatech Co., Ltd. | Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof |
| EP3307720A1 (en) * | 2015-06-12 | 2018-04-18 | Teva Pharmaceuticals International GmbH | Solid state forms of trisodium valsartan: sacubitril |
| CN105037289B (zh) * | 2015-07-17 | 2017-08-22 | 华东理工大学 | 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型 |
| WO2017012600A1 (en) * | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| CN106854187B (zh) * | 2015-12-08 | 2020-04-14 | 苏州晶云药物科技股份有限公司 | 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法 |
| CN106905253B (zh) * | 2015-12-23 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 一种超分子复合物的结晶 |
| CN105753733B (zh) * | 2016-04-15 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | Ahu377的晶型及其制备方法与用途 |
| US10683260B2 (en) * | 2016-09-07 | 2020-06-16 | Nanjing Noratech Pharmaceuticals Co., Ltd. | Crystalline form of sacubitril sodium salt |
| US10857132B2 (en) | 2016-10-10 | 2020-12-08 | Laurus Labs Limited | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof |
| CN110713465A (zh) * | 2017-01-03 | 2020-01-21 | 上海博志研新药物技术有限公司 | ARB-NEPi复合物、晶型、制备方法及应用 |
| CN108299323A (zh) * | 2017-01-11 | 2018-07-20 | 上海迪赛诺药业股份有限公司 | 一种抗心衰共晶化合物的新晶型 |
| WO2018178295A1 (en) | 2017-03-31 | 2018-10-04 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
| WO2019073062A1 (en) | 2017-10-13 | 2019-04-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | TABLET CONTAINING VALSARTAN AND SACUBITRIL |
| WO2019239432A1 (en) | 2018-06-14 | 2019-12-19 | Cipla Limited | Trisodium sacubitril valsartan complex and hot-melt extruded pharmaceutical composition comprising thereof |
| KR20210032437A (ko) | 2018-08-23 | 2021-03-24 | 노파르티스 아게 | 심부전의 치료를 위한 신규한 약제학적 용도 |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| CN111253330B (zh) * | 2020-02-29 | 2023-01-24 | 广州白云山天心制药股份有限公司 | 沙坦类药物的新晶型及其制备方法和用途 |
| KR102858594B1 (ko) * | 2020-10-08 | 2025-09-11 | 한미약품 주식회사 | 사쿠비트릴 및 발사르탄 나트륨염을 포함하는 경구용 고형제제 |
| CN115745904A (zh) * | 2022-09-29 | 2023-03-07 | 浙江美诺华药物化学有限公司 | 一种沙库巴曲缬沙坦钠共晶物的制备方法 |
| CN118141930A (zh) * | 2024-03-26 | 2024-06-07 | 迪沙药业集团有限公司 | 沙坦类药物组合物及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3796763B2 (ja) * | 1994-04-01 | 2006-07-12 | 東ソー株式会社 | 結晶形２，２−ビス（３，５−ジブロモ−４−ジブロモプロポキシフェニル）プロパン及びその製造方法 |
| EP1467728B1 (en) * | 2002-01-17 | 2007-08-22 | Novartis AG | Pharmaceutical compositions comprising valsartan and nep inhibitors |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| FR2897060B1 (fr) * | 2006-02-08 | 2008-07-25 | Sanofi Aventis Sa | Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| US7994238B2 (en) * | 2007-09-04 | 2011-08-09 | General Electric Company | Article and associated method |
| DK2217205T3 (en) | 2007-11-06 | 2015-05-11 | Novartis Ag | DOUBLE-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPER STRUCTURES OF ANGIOTENSINRECEPTORANTAGONIST / blocker (ARB) AND NEUTRAL endopeptidase (NEP) INHIBITOR |
| MA34483B1 (fr) | 2010-08-24 | 2013-08-01 | Novartis Ag | Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante |
| JP5809367B2 (ja) * | 2013-04-24 | 2015-11-10 | あすか製薬株式会社 | レボノルゲストレルの結晶多形α及びその製造方法 |
| AU2015319831B2 (en) | 2014-12-08 | 2019-02-14 | Crystal Pharmatech Co., Ltd. | Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof |
| CN104860894B (zh) * | 2015-06-10 | 2017-05-17 | 北京博全健医药科技有限公司 | 一种抗心衰药lcz696的制备方法 |
| EP3307720A1 (en) | 2015-06-12 | 2018-04-18 | Teva Pharmaceuticals International GmbH | Solid state forms of trisodium valsartan: sacubitril |
| CN105037289B (zh) * | 2015-07-17 | 2017-08-22 | 华东理工大学 | 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型 |
| CN106854187B (zh) * | 2015-12-08 | 2020-04-14 | 苏州晶云药物科技股份有限公司 | 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法 |
-
2015
- 2015-12-08 AU AU2015319831A patent/AU2015319831B2/en active Active
- 2015-12-08 MX MX2017007426A patent/MX383336B/es unknown
- 2015-12-08 PT PT15843405T patent/PT3229799T/pt unknown
- 2015-12-08 WO PCT/US2015/064432 patent/WO2016049663A1/en not_active Ceased
- 2015-12-08 SI SI201530569T patent/SI3229799T1/sl unknown
- 2015-12-08 TR TR2019/00360T patent/TR201900360T4/tr unknown
- 2015-12-08 DK DK15843405.0T patent/DK3229799T3/en active
- 2015-12-08 CA CA2970192A patent/CA2970192C/en active Active
- 2015-12-08 HU HUE15843405A patent/HUE043014T2/hu unknown
- 2015-12-08 JP JP2017530598A patent/JP2017537120A/ja active Pending
- 2015-12-08 CN CN201910761992.2A patent/CN110938042B/zh active Active
- 2015-12-08 EP EP18192712.0A patent/EP3443960A1/en not_active Withdrawn
- 2015-12-08 US US15/528,153 patent/US9957240B2/en active Active
- 2015-12-08 CN CN201580002782.5A patent/CN105873586B/zh active Active
- 2015-12-08 ES ES15843405T patent/ES2706948T3/es active Active
- 2015-12-08 CN CN201910761979.7A patent/CN110922366B/zh active Active
- 2015-12-08 EP EP15843405.0A patent/EP3229799B1/en not_active Revoked
- 2015-12-08 PL PL15843405T patent/PL3229799T3/pl unknown
-
2017
- 2017-06-07 IL IL252740A patent/IL252740A0/en unknown
-
2018
- 2018-03-18 US US15/924,250 patent/US10508087B2/en active Active
- 2018-07-03 JP JP2018127088A patent/JP2018168180A/ja active Pending
-
2020
- 2020-07-22 IL IL276233A patent/IL276233B2/en unknown
- 2020-09-11 JP JP2020152967A patent/JP2020203936A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE043014T2 (hu) | Valzartánt és AHU 377-et tartalmazó trinátrium szupramolekuláris komplex kristályos formái, és az ezekhez tartozó eljárások | |
| HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
| KR102254062B9 (ko) | 삼나트륨 발사르탄:사쿠비트릴의 고체 형태 | |
| HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
| LT3191461T (lt) | 6-karboksi-2-(3,5-dichlorfenil)-benzoksazolo kristalinės kietos formos | |
| HUE039899T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származékai, ennek polimorf formái és eljárások ezek alkalmazására | |
| HUE042449T2 (hu) | Új 4-metoxi-pirrolszármazékok vagy sóik és az azokat tartalmazó gyógyászati készítmények | |
| HUE054042T2 (hu) | Pirazolvegyületek és eljárás a vegyületek elõállítására és alkalmazásuk | |
| EP3174874A4 (en) | BERBERINSALZE, URSODEOXYCHOLSALZE AND COMBINATIONS, METHOD FOR THE PRODUCTION AND THE APPLICATION THEREOF | |
| HUE054694T2 (hu) | Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszerei | |
| HUE046509T2 (hu) | Új vegyület és eljárás | |
| HUE040304T2 (hu) | 2-Amino-6-(difluor-metil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridinek, mint bace1 inhibitorok | |
| HUE050306T2 (hu) | Orális vízfelvevõ kompozíció, és ennek eljárásai | |
| IL255178B (en) | Strigolactones or their derivatives for use in increasing the yield of a cultivated plant | |
| HUE040022T2 (hu) | Eljárás (S,S)-szekoizolaricirezinol diglükozid és (R,R)-szekoizolaricirezinol diglükozid elõállítására | |
| HUE054815T2 (hu) | 3,5-Difenil-diazol vegyületek vízoldható származékai | |
| HUE052968T2 (hu) | Liposzóma kompozíció és annak elõállítási eljárása | |
| HUE045192T2 (hu) | 6-morfolinil-2-pirazolil-9H-purin származékok és felhasználásuk PI3K inhibitorokként | |
| HUE050565T2 (hu) | Pirazolotiazol vegyület és azt tartalmazó gyógyszer | |
| HUE058726T2 (hu) | Új nilotinib sók és azok polimorfjai | |
| ZA201803250B (en) | New 5-azido-5-deoxy-2 :3-isopropylidene-d-arabinose compounds; their method of manufacture and their use for the synthesis of ara-n3, kdo-n3 and 4ekdo-n3 | |
| DK3398946T3 (da) | Salt af morpholin-derivat og krystallin form deraf, samt fremstillingsfremgangsmåde, farmaceutisk sammensætning og anvendelse af samme | |
| DK3207023T3 (da) | Fremgangsmåde til fremstilling af 1-(3,5-dichlorphenyl)-2,2,2-trifluorethanon og derivater deraf | |
| HUE056038T2 (hu) | Cefalosporin-származék sója, annak kristályos szilárd alakja és eljárás annak elõállítására | |
| HUE049284T2 (hu) | Eljárás (S)-2-acetiloxipropionsav és származékai elõállítására |